The Omega-3 Index is a blood biomarker defined as the amount of the long-chain marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) contained in red blood cell (erythrocyte) membranes, expressed as a percentage of total fatty acids. It was proposed by Harris and von Schacky in 2004 and is determined from a small blood sample (including a finger-prick dried-blood spot) using a standardized analytical method (the HS-Omega-3 Index). Because erythrocyte fatty-acid composition turns over slowly, the index reflects a person's long-term EPA + DHA status and tissue levels rather than recent intake, with commonly cited target values of 8-11%.
In prospective cohort studies and pooled analyses spanning dozens of cohorts, higher blood levels of EPA + DHA have been consistently associated with lower all-cause and cardiovascular mortality - across ten cohorts an Omega-3 Index near 8% carried roughly 30% lower fatal coronary heart disease risk than one near 4% - and a low index meets proposed criteria for a novel cardiovascular risk marker; lower erythrocyte omega-3 levels have also been linked to smaller brain volumes and poorer cognitive measures during aging. However, several large randomized supplementation trials produced neutral results for clinical endpoints, a discrepancy attributed partly to trial-design and bioavailability issues rather than to a lack of biomarker relevance, and a 2024 UK Biobank analysis tied regular fish-oil use in people without cardiovascular disease to higher atrial fibrillation and stroke risk. Much of the strongest evidence is observational association rather than proof that raising the index itself causes better outcomes. This evidence describes the EPA + DHA biomarker (the Omega-3 Index) and its measurement in general, not this specific commercial test product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“a lower Omega-3 Index was associated with increased risk for total mortality and ischemic stroke”
“EPA and DHA were associated with reduced mortality independent of other risk factors”
“risk for death from all causes was significantly lower (by 15-18%, at least p < 0.003) in the highest vs the lowest quintile for circulating long chain (20-22 carbon) omega-3 fatty acids (eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids).”
“The Omega-3 Index was inversely associated with risk for CHD mortality. An Omega-3 Index of > or = 8% was associated with the greatest cardioprotection, whereas an index of < or = 4% was associated with the least.”
“Those in the highest (>6.8%) compared to those in the lowest Omega-3 Index quintiles (<4.2%) had a 34% lower risk for death from any cause and 39% lower risk for incident CVD.”
“Higher RBC levels of marine n-3 PUFAs were associated with reduced risk for all-cause mortality. These findings support the beneficial relationship between the Omega-3 Index and health outcomes.”
Research describes the active mechanism and is not a claim about this specific product.
Across large prospective cohorts and meta-analyses, lower grip strength is consistently…
Across large studies, dysregulated cortisol patterns track with worse health: a…
Large prospective cohorts and meta-analyses consistently link higher serum GGT, even…
Higher fasting insulin and HOMA-IR reflect greater insulin resistance, a central feature…
Yes — its active compound is linked to 22 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.